The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits

被引:13
作者
Shinno, Keisuke [1 ]
Kurokawa, Kazuya [1 ]
Kozai, Seiko [1 ]
Kawamura, Akio [1 ]
Inada, Katsuhiro [1 ]
Tokushige, Hideki [1 ]
机构
[1] Senju Pharmaceut Co Ltd, Osaka, Japan
关键词
Brimonidine distribution; free drug concentration; pigmented rabbit; retina/choroid; vitreous body; GLAUCOMA; MELANIN; EYES; NEUROPROTECTION; DEGENERATION; RECEPTORS; AGONISTS; BINDING; MONKEY;
D O I
10.1080/02713683.2016.1238941
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Several studies showed that repeated topical administration of brimonidine tartrate ophthalmic solution reached the human vitreous concentration above 2 nM, which is the concentration necessary to activate the (2)-adrenergic receptor. The purpose of this study was to elucidate the relationship of the brimonidine concentration in the vitreous body to the free concentration in the retina/choroid which is the target site of brimonidine on neuroprotective effect after topical administration. Materials and methods: Brimonidine concentrations in the eye tissues of pigmented rabbits were determined following single ocular administration of 0.1% brimonidine tartrate ophthalmic solution at pH 7.3. Binding affinity of brimonidine to melanin and melanin content in the retina/choroid of pigmented rabbits was also examined. The concentration of free brimonidine which did not bind to melanin in the retina/choroid was calculated using the binding parameters to melanin. Results: Topically applied brimonidine rapidly distributed to intraocular tissues. The elimination rate from melanin-containing tissues such as the iris/ciliary body and retina/choroid was slower than the aqueous humor and vitreous body in pigmented rabbits. In both the anterior and posterior retina/choroid, the free brimonidine concentrations were over 100-fold lower than the total concentrations. The concentrations in the vitreous body closely matched to the free concentrations in the posterior retina/choroid. Simulated free concentrations in the posterior retina/choroid were gradually increased when 0.1% solution was instilled twice daily. Conclusion: The present data indicated that the brimonidine concentration in the vitreous body was comparable to the free concentration in the posterior retina/choroid. This suggests that the vitreous concentration can be a surrogate indicator of the free brimonidine concentration in the posterior retina/choroid. From the present findings, it is expected that multiple instillation of brimonidine tartrate ophthalmic solution may produce the sufficient free concentration for activation of the (2)-adrenergic receptor in the retina/choroid in human.
引用
收藏
页码:748 / 753
页数:6
相关论文
共 22 条
[1]  
ACHEAMPONG AA, 1995, DRUG METAB DISPOS, V23, P708
[2]   Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit,and rat eyes [J].
Acheampong, AA ;
Shackleton, M ;
John, B ;
Burke, J ;
Wheeler, L ;
Tang-Liu, D .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :421-429
[3]   Brimonidine - A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension [J].
Adkins, JC ;
Balfour, JA .
DRUGS & AGING, 1998, 12 (03) :225-241
[4]  
BERLIE JR, 1995, INVEST OPHTH VIS SCI, V36, P1885
[5]   Preclinical evaluation of brimonidine [J].
Burke, J ;
Schwartz, M .
SURVEY OF OPHTHALMOLOGY, 1996, 41 :S9-S18
[6]  
Buszman Ewa, 2003, Acta Pol Pharm, V60, P257
[7]   Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes [J].
Durairaj, Chandrasekar ;
Chastain, James E. ;
Kompella, Uday B. .
EXPERIMENTAL EYE RESEARCH, 2012, 98 :23-27
[8]   Ocular Drug Delivery [J].
Gaudana, Ripal ;
Ananthula, Hari Krishna ;
Parenky, Ashwin ;
Mitra, Ashim K. .
AAPS JOURNAL, 2010, 12 (03) :348-360
[9]   Vitreous concentration of topically applied brimonidine-Purite 0.15% [J].
Kent, Alexander R. ;
King, Lowery ;
Bartholomew, Luanna R. .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 22 (04) :242-246
[10]   Vitreous concentration of topically applied brimonidine tartrate 0.2% [J].
Kent, AR ;
Nussdorf, JD ;
David, R ;
Tyson, F ;
Small, D ;
Fellows, D .
OPHTHALMOLOGY, 2001, 108 (04) :784-787